AAVL Profile
Avalanche Biotechnologies, Inc. (AAVL) was a clinical-stage biotechnology company focused on the development of gene therapies for the treatment of ophthalmologic diseases. The company was acquired by Annapurna Therapeutics in 2016 and is no longer publicly traded.
AAVL was focused on developing therapies for the treatment of age-related macular degeneration (AMD), a leading cause of blindness in the elderly. The company's approach involved the use of adeno-associated viruses (AAV) to deliver therapeutic genes to the eye.
AAVL's lead product candidate was AVA-101, which was in phase 2 clinical trials for the treatment of wet AMD. The company's technology had the potential to be a game-changer in the treatment of AMD, as it offered the possibility of long-lasting effects with a single administration.
While AAVL was an early-stage biotechnology company with limited revenue and significant research and development expenses, it had a strong intellectual property portfolio and a promising pipeline of product candidates. The acquisition by Annapurna Therapeutics provided AAVL with the financial resources and expertise needed to further advance its research and development programs.
Overall, AAVL was an innovative biotechnology company focused on developing gene therapies for the treatment of ophthalmologic diseases. Its acquisition by Annapurna Therapeutics reflects the potential of its technology and the interest of larger pharmaceutical companies in the development of gene therapies.
|
